Windward Bio raised $200M in a Series A funding round led by OrbiMed Novo Holdings and Blue Owl Healthcare Opportunities to develop a phase 2-ready monoclonal antibody for asthma and COPD.

Jan 10, 2025•8 months ago

Amount Raised

$200 Million

Round Type

series a

BaselBiopharmaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Investors

Pivotal Bio Venture PartnersQuan CapitalSr OneBlue Owl Healthcare OpportunitiesOrbi Med Novo Holdings

Description

Windward Bio officially launched with $200 million in Series A financing. The funding will support the development of its lead program, a long-acting anti-TSLP monoclonal antibody, and additional discovery pipeline for bispecifics.

Company Information

Company

Windward Bio

Location

Basel, Basel-Stadt, Switzerland

About

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends